Year Founded
2005
Ownership
Public
Stage
Phase 3
Modalities
Engineered cytokinesSmall moleculeOther

Eusol Biotech General Information

Lead candidate ES135 (rhFGF1) showed promising results in Phase 3 trials for spinal cord injury, demonstrating improved motor recovery and reduced myelomalacia. The company also has SM-1 in Phase 3 for sleep disorders.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office

Drug Pipeline

ES135
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Eusol Biotech's pipeline data

Book a demo

Key Partnerships

Far-Eastern Memorial Hospital, Anxo Pharmac

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Eusol Biotech Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Eusol Biotech's complete valuation and funding history, request access »